• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Compulsory Licensing of Pharmaceutical Patents System from the Perspective of Public Interest-Public Health in China

    2020-07-09 08:49:12ZhangYuboYuanHongmei
    亞洲社會(huì)藥學(xué)雜志 2020年1期

    Zhang Yubo,Yuan Hongmei

    (School of Business Administration,Shenyang Pharmaceutical University,Shenyang 110016,China)

    Abstract Objective To study the types and acquisition paths of drug data in the administrative act of compulsory licensing of pharmaceutical patents so as to provide data support for the implementation of compulsory licensing of pharmaceutical patents from the perspective of public interest-public health in China.Methods Situation of compulsory licensing of pharmaceutical patents in the context of public interest-public health in China was selected,combined with international conventions and the principle provisions of relevant laws,and cases of compulsory licensing of pharmaceutical patents in foreign countries were reviewed to extract drug-related data of compulsory licensing of pharmaceutical patents.Results and Conclusion According to the analysis of China’s compulsory licensing of pharmaceutical patents theory and legal provisions,the data could be divided into five categories for compulsory licensing of pharmaceutical patents in China:diseases,drugs,patents,generic drug enterprises,and licensing fees.Although,some data are traceable.There were also problems in obtaining data or inconsistent standards in five levels of compulsory licensing of pharmaceutical patents in the context of public interest-public health.It was not conducive to the implementation of compulsory licensing of pharmaceutical patents in China.Thus,it should be further established a unified data support system at the national level,specifying the standard of licensing fee,implementing relevant laws and regulations.

    Keywords:compulsory license; public interest; public health; data acquisition

    The compulsory licensing of pharmaceutical patents system has been recognized by the international community due to its incorporation into TRIPS.Some countries,such as the United States,India,and Thailand have used this system in practice and obtained good social benefits.This system is not strange in China,but there is no precedent of using this system in practice.Nowadays,the conditions for implementing the compulsory licensing of pharmaceutical patents system are mature.However,the implementation of this system involves many important and sensitive issues,such as the complex drug data types with specialty.Thus,in order to ensure the legality,science and order,accurate research and demonstration on the types of drugs involving data and acquisition paths become one of the necessary procedures to launch the preliminary preparation of compulsory licensing of pharmaceutical patents in China.Based on the research of theory and system,some drug data types and access path were studied to provide support for realizing the drug patent compulsory license under the condition of public interest-public health.Thus it can promote the implementation of the compulsory license,drug accessibility,and improve the protection of public health in China.

    1 The public interest-public health and compulsory licensing of pharmaceutical patents

    As an important part of the intellectual property system,TRIPS agreement stipulates the principles for the compulsory licensing of pharmaceutical patents[1],giving each country the right of free decision-making and it can design a compulsory licensing system of pharmaceutical patents according to its own national conditions.In practice,many countries explore the system design suitable for their own national conditions,and have achieved significant results.In view of the different situations of compulsory licensing of pharmaceutical patent and the particularity of each situation,it is believed that selecting a specific situation for research based on China’s national conditions is necessary.After repeated deliberation,we choose public interest-public health as the research entry point,and the reasons are the followings.

    First of all,the essential attribute of compulsory licensing strictly limits the start-up situation.Compulsory licensing is to deprive citizens’ legal private rights through administrative power.Thus,both TRIPS agreement and the laws of all countries in the world have made extremely strict regulations on the starting situation of this administrative act[2].They require that the different situation should be dealt with respectively.Therefore,a more broad and independent research horizon — the public interest-public health is selected as the research situation.

    The second is the international convention system design requirements.In 2001,all the member countries signed the Declaration on TRIPS and Public Health in Doha[3],which recognized that public health problems seriously affected many developing and the poorest countries,especially those suffering from AIDS,tuberculosis,malaria and other infectious diseases.In 2005,the WTO General Council adopted the Revised TRIPS Protocol,which elevated the contents made in Doha Health Declaration into a formal provision of TRIPS agreement in the form of a treaty,marking that public health,an integral part of public interest,became the legal basis for members to issue compulsory licensing of pharmaceutical patent.

    Then,the specific background of compulsory licensing in China was taken into consideration.According to China’s patent law,China’s patents compulsory licensing was divided into six situations,as shown in Table 1.

    Table 1 China’s patent law on patent licensing situations

    Firstly,the domestic patent compulsory licensing of the basic issues of theory and application should be clarified.Then,export dimensions should be clarified too.Based on the above considerations,this article selected (3) as the research situation.Due to the rare national emergency,the public interests are taken as the research key.In view of the fact that public interests in the world are within the scope of public health category of compulsory licensing of pharmaceutical patents,this paper focuses on public health in order to be more targeted and operable.Therefore,the chosen situation is public interest-public health.

    2 Elements of compulsory licensing of pharmaceutical patents from the perspective of Public interest-public health

    2.1 Drug factors

    Base on the trade-related intellectual property agreement amendment protocol,drug is defined as a patented product of pharmaceutical industry or a product produced by a patented process for public health.The active ingredients of the products and the diagnostic kits are also included[4].

    According to the Drug Administration Law of the People’s Republic of China in 2019,drugs refer to substances used for the prevention,treatment and diagnosis of human diseases,for the purpose of regulating human physiological functions and for prescribing indications,functions,usages and dosage,including traditional Chinese medicine,chemical drugs and biological products.Meanwhile,the detailed rules for the implementation of the patent law in article 73 pointed out that the patent drugs refers to any patented products used for public health or direct access to products in accordance with the patent method,including the patent right of manufacture for active ingredients of the products and diagnostic products.

    It can be found from the cases of compulsory licensing of pharmaceutical patents in India,Brazil,Thailand and other developing countries that the selection of target drugs for compulsory licensing should meet the following conditions,shown in Table 2.

    Table 2 Conditions of compulsory licensing of pharmaceutical patents in various countries

    According to the existing practice examples of compulsory licensing in foreign countries,it is believed that the patented drugs suitable for compulsory licensing should meet the following conditions.First,the substitutability of patented drugs is low.When the public are faced with health problems,the irreplaceable and important role of patented drugs is the first requirement for compulsory license of the target drugs.Second,the accessibility of the patented drug is poor.When the public are faced with health problems,they have a greater demand for patented drugs,so patented drugs must have adequate access.Third,the affordability of the patented drug is low.If the price of patented drugs is far beyond the public’s expectation,many patients will not receive good treatment,which seriously threatens the national health and quality of life.

    2.2 Patent elements

    In the term of patent protection,the following stipulations were made in article 28 of the TRIPS agreement.A patentee should have the following exclusive rights.For the product patent,the patentee has the right to prohibit the third party from engaging in these acts:manufacturing,using,and providing for the sale,selling,or importing the product for the above purposes without his consent.For the method patent,the patentee has the right to prohibit third parties from using the method without his consent as well as selling or importing products directly obtained by the method.The patentee shall have the right to assign or transfer patent through inheritance,and to conclude a license contract.

    Invention means creation,utility model and designs according to the patent law of China.It refers to a new technical proposal for a product,a method or an improvement.The method invention includes a technical proposal for an operation method,a manufacturing method and a technological process,etc.The term utility model refers to a new technical scheme for the shape,construction or combination of a product that is fit for use.Meanwhile,appearance design refers to the new design made on the shape,pattern or their combination.Besides,it is the combination of color,shape and pattern,which is rich in aesthetic feeling and suitable for industrial application.Therefore,it is believed that the patent of a drug suitable for compulsory licensing should have such condition that the patent related to the drug must be authorized in China and it is in an effective state.

    2.3 Definition of generic drug enterprise qualification

    The appendix of the revised protocol to the TRIPS agreement stipulated the criteria and methods for assessing the lack of productive capacity of importing countries[5].The production capacity of the pharmaceutical industry is as follows.

    The least developed member states are considered to have no or insufficient manufacturing capacity in the pharmaceutical industry.For other member states that are eligible for import,it can be determined by one of the following ways that they do not have or lack the production capacity for the relevant drugs.The member state has proved that it has no production capacity in the pharmaceutical industry,but it has some production capacity in the industry.The member state has been investigated that capacity is currently insufficient to meet its own needs except for the production capacity owned or controlled by the patent owner.The system may no longer apply to this member state when it is proved that the productive capacity is sufficient to meet its needs[6].

    Article 48 of the Patent Law in China provides that under any of the following circumstances,the patent administration department under the State Council may grant a compulsory licensing to exploit the patent for invention or utility model upon the application of any qualified entity or individual.The above having the conditions for implementation indicates the qualifications of generic drug enterprises in compulsory licensing of pharmaceutical patents.Firstly,it should have the technical conditions to manufacture patented products with patented methods.Secondly,it has the capital and assets conditions.Thirdly,it should meet the market supervision requirements for manufacturing patented products with patented methods,and have the market access qualification.If the exploitation of the patent by the licensee under compulsory licensing belongs to the licensee’s import of the patented product,the conditions for implementation mentioned in article 48 should be interpreted as follows.First,the import and export of the patented technology and product should comply with the requirements of the import and export control regulations of the relevant country.Second,it must have proof of funds.

    2.4 Definition of license fee

    In 2012,Indian Patent Office issued a compulsory license for the anti-cancer drug Nexamei,and Indian generic drug company Natco had to pay Bayer a patent fee of 6% of sales[7].The Thai government issued a compulsory license for Efavirenz.The government recommended a license fee of 0.5% of the generic drug price.The amount of the generic drug price was determined by the additional negotiation between the licensee and the patentee.In 2003,in order to import the generic drug of the patented drug ARV from the Indian company CIPLA,Malaysia issued a compulsory license for the import of Zidovudine,Didanosine and Zidoramide Difudine from India by the Ministry of Domestic Trade and Consumer Affairs within 2 years.As to compensation,the Ministry of Health proposed to give the patentee 4% of the actual shipment value per year,but the patent holder did not accept this compensation[8].By summarizing the calculation of the compulsory license fee in various countries,four modes were sorted out[9-10].They are UNDP mode,Canadian mode,fixed ratio method,and tort compensation method.

    2.4.1 UNDP model

    The UNDP Human Development Report recommends a simple system of patent royalty guidelines,which is primarily for developing countries with the aim of ensuring the transparency and predictability of compulsory licenses.The basic compensation is 4% of the generic drug price,which can be increased or decreased by 2% depending on the degree of innovation of the drug or the government’s investment in research and development.Therefore,the compensation fee is 2% to 6% of the generic drug price.

    2.4.2 Canadian model

    The Canadian government has developed a guideline on royalty for compulsory licensing of pharmaceutical patents imported by countries that lack pharmaceutical capabilities.According to the national ranking in the UNDP Human Development Index (HDI),the compensation ratio is 0.02% to 4%.For most developing countries,the ratio is less than 3%,and for most African countries,the ratio is less than 1% (Compulsory license fee ratio=0.04 * (178 -Drug importing country HID ranking)/ 177).

    2.4.3 Fixed ratio method

    It refers to the determination of the compensation fee for compulsory license according to a certain proportion of the sales of patented products.There are two ways.One is to determine the proportion of patent royalties by the discretionary authority to exercise discretion in specific cases.The other is to determine the proportion of royalties through legislation or lawsuit.

    2.4.4 Tort compensation method

    It is originated from the Diddell v.Vickers case in the United Kingdom.According to this method,the compensation for patent compulsory licenses should be calculated based on the amount of compensation that should be paid for infringement of patent rights.

    At present,Patent Law of China,Patent Law Implementation Rules and Patent Implementation Compulsory License Measures have not clearly explained the reasonable use fee.Besides,there is no compulsory license fee measurement example.So when the license is used to carry out the enforcement in the future,the measurement of the license fee can be drawn from the above four models in foreign countries.In the case of simulation,this paper also studied the data points involved in the four calculation methods of license fee to provide reference for the future compulsory license in China.

    3 Public interest-public health compulsory license program data design

    The starting point of this study is compulsory licensing of pharmaceutical patents in the public interest-public health context.The types of data needed by compulsory licensing of pharmaceutical patents and the acquisition path in the public interestpublic health context are chosen according to the relevant legal provisions mentioned references.After the previous analysis of the legal provisions and examples of compulsory licenses,the data are finally classified into five categories,which include disease data,drug data,patent data,generic drug enterprise data and license fee data.

    3.1 Selecting disease data

    In terms of diseases,data on seven aspects are selected,including macroscopic statistics of diseases,chronic non-communicable diseases,sexually transmitted diseases,AIDS,viral diseases,tuberculosis,parasitic diseases and infectious diseases.Among them,the Yearbook of National Health and Family Planning Commission Statistical provided macroscopic statistics on 28 infectious diseases and deaths from the reports of Class A and B.The number of incidence,mortality and death of 28 infectious diseases are shown in each year or province.The 28 infectious diseases are classified into different age groups,genders,and statistics on the mortality of urban and rural areas.At the Center for Disease Control and Prevention of China,the status of chronic non-communicable diseases,sexually transmitted diseases and AIDS can be checked.In addition,monitoring dynamic information on viral diseases,tuberculosis and parasitic diseases can be provided as well.Last,the Emergency Command Center for Public Health can also provide an epidemic report when an infectious disease occurs.

    Thus,it is not difficult to observe disease conditions from various channels and comprehensive information to support the data acquisition and analysis of the compulsory licensing program.

    3.2 Selecting drug data

    In terms of drugs,the substitutability,accessibility,and affordability are the key factors to determine whether a patented drug could become a public interest-public health target.As to substitutability,it should include three levels of data such as technical information,safety information and market information.The Drug Evaluation Center of the State Drug Administration is responsible for conducting technical reviews of drug registration applications and providing technical information services.The National Adverse Drug Reaction Monitoring Center can get the reports about adverse drug reaction.The health administrative department can obtain the information of market occupancy through public hospitals.In addition,the information on the supply of medicines in public hospitals and retail pharmacies in key cities can also be obtained through the intranet and China Medical Industry Information Center.For accessibility,it can be considered from the four levels of domestic production capacity,production,import volume and reserves.Local Drug Regulatory Departments master production capacity information of pharmaceutical personnel and equipment.Meanwhile,the production information is reported by enterprises and the import quantity information is supervised by the Port Drug Supervision Bureau which allows the import.The State Material Reserve Bureau,a subordinate unit of the National Development and Reform Commission,prepares a catalogue of national strategic material reserves,and supervises the quantity,quality and storage safety of the reserve strategic materials so that it can grasp the information on the amount of relevant medicines.In terms of affordability,it can be considered from the three levels of sales price,patient payment ability,and medical insurance reimbursement.The drug sales price data mainly includes the drug bidding price of the health administrative department and the recruitment platform.Patients’ capability of paying mainly includes the total health expenditure per capita,health care expenditure per capita and proportion in all provinces provided by the Health and Health Commission,as well as GDP per capita,income per capita and consumption expenditure provided by the National Bureau of Statistics.The medical insurance reimbursement data mainly includes the medical insurance reimbursement information of the National Basic Medical Insurance,the Work Injury Insurance and Maternity Insurance Drug List provided by the Ministry of Human Resources and Social Security,and the annual medical insurance expenditure per capita.In addition,personal payment ratio data of the B medicines are provided by the municipal social security bureau.

    Through the above analysis,it is not difficult to find that the situation of drugs can be observed from a variety of channels and information to provide support for data acquisition and analysis of compulsory licensing procedures.

    3.3 Selecting patent data

    In the aspect of patents,we need to know the information of drugs,the basic information of patents,the technical information of patents,and the legal status of patents.

    Pharmaceutical patent information can be obtained from the publication of patents related to drug registration of the State Drug Administration and the collection of listed drug catalogues in China.Information on the basic technology and legal status of patents can be obtained from the patent retrieval module of the website of the State Intellectual Property Office of China and IncoPat Patent Database.Information on patent challenges can be retrieved from the intellectual property module of the Judgment Document of China’s Supreme People’s Court’s.

    Through the above analysis,it is not difficult to find that patents can be observed from a variety of channels and information to provide support for data acquisition and analysis of compulsory licensing procedures.

    3.4 Data selection of generic pharmaceutical enterprises

    As to generic pharmaceutical enterprises,their qualification,copying ability,and cost accounting of generic drugs are essential elements for them to be the candidates for compulsory license of pharmaceutical patents.Qualifications of generic pharmaceutical enterprises and their business license information can be obtained from the State Administration of Market Supervision-State Enterprise Credit Information Publicity System.But the conclusion document of on-the-spot inspection of copying ability and the production compatible with the production of drugs can be consulted with the local drug regulatory authorities,or through the Shenzhen Stock Exchange and Shanghai Securities Exchange.Information acquired by exchanges can be used to measure the imitation ability of enterprises,and the information of enterprises applying for production registration can also be known in the information disclosure module of the drug evaluation center.

    In addition,the administrative matters acceptance service module can inquire about the progress of drug registration according to the drug acceptance number.As for the cost accounting of generic drugs,it is often necessary to check the progress of drug registration according to the drug acceptance number.It takes selfreport to get it.Through the above analysis,it is easy to find that the situation of generic pharmaceutical enterprises can be observed from a variety of channels and information for data acquisition and analysis of compulsory licensing procedures.

    3.5 Selecting data of license fee

    In terms of licensing fee,because there is no precedent in China,we can only learn from some models abroad,mainly the above four models:UNDP model,Canadian model,fixed proportion law,tort damage compensation law.The formula of UNDP model means Licensing fee=Generic drug price * (2%-6%).The formula of Canadian model is Licensing fee=Generic drug price * Licensing fee ratio.Licensing fee ratio=0.04 * (178 -HID ranking of drug importing countries)/ 177.Its formula of fixed proportion method is Licensing fee=Sales volume * A certain proportion (case specific analysis,recommended 4%-6%).Tort compensation method includes the following ways,such as calculating licensing fee based on the actual loss of the patent holder,Licensing fee=Reasonable profit of the unit patented product * Sales volume of the infringed product.The second is based on the profits obtained from the infringement,Licensing fee=Operating profit of the unit infringed product * Sales volume of infringed products.The third is calculated by the people’s court with fixed compensation,Licensing fee=More than 10 000 yuan,less than 1 million yuan.The calculation is based on the cost recovery of original research and development of drugs.The specific data acquisition methods of each formula have been described before.The formula can be obtained from various channels and information to calculate the required data.Therefore,the licensing fees of different models can be calculated to support the data acquisition and analysis of compulsory licensing procedures.

    4 Conclusions and suggestions

    The design of the international drug patent compulsory licensing system is analyzed and combined with our own national conditions.And then the situation of public interest-public health compulsory licensing is chosen as the starting point.According to the international conventions and the relevant laws and regulations of China,the connotation of public interest-public health in the context of our country was discussed,and the cases of compulsory licensing of pharmaceutical patents in India,Brazil and Thailand were analyzed to design the implementation of compulsory licensing of pharmaceutical patents.Data acquisition path can provide data support to promote the follow-up implementation of compulsory license of pharmaceutical patents in China.But it can be seen from the article that although some data are traceable,there are still some data without uniform provisions.So some suggestions are put forward.

    4.1 Establishing a unified data support system

    It can be seen from the fourth part of this article that drug data of patent compulsory licensing is complex,involving the official data of National health commission,food and drug administration,the state intellectual property office,the national bureau of statistics,ministry of industry,the national development and reform commission,the general administration of customs as well as other administrative agencies.It also involve in other technical data such as epidemic,pharmaceutical production consistency,generic drugs registration and drug patents,medical insurance as well as market prices and raw material supply.Corresponding data support system should be established by the government to improve the feasibility of compulsory licensing of pharmaceutical patents.

    4.2 Specifying the license fee standard

    The reasonable royalty in the patent law needs clear and operable standards.TRIPS agreement stipulates that adequate compensation should be given on the premise of the economic value factors of the authorization,but it does not define the method or standard.This article has mentioned that India,Thailand,Canada and Malaysia have their own compulsory licensing fees for drugs.The above information can be used as the preparation for China to determine the compulsory licensing fees for drugs.

    4.3 Realizing the systematic and scientific compulsory license law

    The fourth revision of the patent law can be taken as an opportunity to integrate and improve the regulatory system of compulsory licensing of pharmaceutical patents.In setting up the legal standard system,provisions of the legislation law on the scope of legislative power should be strictly followed,and the types,causes,conditions and main procedures of the compulsory licensing of pharmaceutical patents system must be further clarified.According to the needs,the administrative regulations of compulsory license or compulsory licensing of pharmaceutical patents should be formulated to refine procedural and operational regulations[3].A regulatory system of compulsory licensing of pharmaceutical patents should be formed,which is clear in legal effect,concise in expression,and easy to operate.

    两个人免费观看高清视频| 日韩中字成人| 久久综合国产亚洲精品| 一边摸一边做爽爽视频免费| 午夜免费男女啪啪视频观看| 中文天堂在线官网| 国产精品欧美亚洲77777| 美女内射精品一级片tv| av在线app专区| 欧美日本中文国产一区发布| 日本午夜av视频| 黑人猛操日本美女一级片| 免费观看的影片在线观看| 亚洲人成网站在线播| 久久久久久久久久成人| 欧美人与性动交α欧美精品济南到 | 一区二区三区四区激情视频| 婷婷色av中文字幕| 人人妻人人爽人人添夜夜欢视频| 最新的欧美精品一区二区| 精品久久蜜臀av无| 久久久久精品性色| 日韩视频在线欧美| 亚洲精品乱码久久久久久按摩| 亚洲综合色网址| 久久午夜福利片| 中文字幕免费在线视频6| 国产精品99久久久久久久久| 日本色播在线视频| 91久久精品国产一区二区成人| 国产无遮挡羞羞视频在线观看| 国产又色又爽无遮挡免| 欧美日韩在线观看h| 精品久久久久久久久av| 国产日韩欧美视频二区| 另类亚洲欧美激情| 国产永久视频网站| 久久影院123| 日韩 亚洲 欧美在线| 成人综合一区亚洲| 男女啪啪激烈高潮av片| 18禁在线播放成人免费| 亚洲国产欧美日韩在线播放| 久久久国产精品麻豆| 午夜av观看不卡| tube8黄色片| 不卡视频在线观看欧美| 欧美精品一区二区免费开放| 久久 成人 亚洲| 久久久久久久大尺度免费视频| 不卡视频在线观看欧美| 精品久久久久久电影网| 最后的刺客免费高清国语| 黑人巨大精品欧美一区二区蜜桃 | freevideosex欧美| 综合色丁香网| 蜜桃久久精品国产亚洲av| 少妇高潮的动态图| 精品久久久久久电影网| 一区二区三区乱码不卡18| 久久久久久久久久久丰满| 人人妻人人澡人人爽人人夜夜| 99热国产这里只有精品6| 国产黄片视频在线免费观看| av线在线观看网站| 免费观看在线日韩| 亚洲综合色网址| 日韩亚洲欧美综合| 亚洲人成网站在线观看播放| 最新的欧美精品一区二区| 制服人妻中文乱码| 久久99热6这里只有精品| 国产精品不卡视频一区二区| av福利片在线| 性色avwww在线观看| 极品少妇高潮喷水抽搐| 全区人妻精品视频| 黑人猛操日本美女一级片| 久久精品夜色国产| 精品人妻熟女毛片av久久网站| 国产一区二区三区av在线| 色视频在线一区二区三区| 婷婷色av中文字幕| 久久久久国产网址| 国产精品国产三级专区第一集| 精品久久久久久电影网| 亚洲欧美成人综合另类久久久| 青青草视频在线视频观看| 国产 精品1| 久久久久久人妻| 亚洲国产精品国产精品| 熟女av电影| 精品少妇黑人巨大在线播放| 精品国产露脸久久av麻豆| 亚洲av欧美aⅴ国产| 午夜日本视频在线| 极品人妻少妇av视频| 高清av免费在线| 大片免费播放器 马上看| 在线免费观看不下载黄p国产| 久久精品国产亚洲av天美| 亚洲欧美成人精品一区二区| 欧美xxⅹ黑人| 国产一区二区在线观看日韩| 日本猛色少妇xxxxx猛交久久| av卡一久久| 欧美3d第一页| 国产成人精品一,二区| 大香蕉久久网| 日产精品乱码卡一卡2卡三| 自拍欧美九色日韩亚洲蝌蚪91| 亚洲精品日本国产第一区| 久久这里有精品视频免费| 一级,二级,三级黄色视频| 国产精品女同一区二区软件| 乱人伦中国视频| 免费观看av网站的网址| 久久影院123| 如何舔出高潮| 亚洲人成77777在线视频| 成人国语在线视频| 秋霞在线观看毛片| 国产免费现黄频在线看| 久久久国产一区二区| 亚洲人与动物交配视频| 伦理电影大哥的女人| 桃花免费在线播放| 少妇人妻精品综合一区二区| 80岁老熟妇乱子伦牲交| 日日摸夜夜添夜夜添av毛片| 成年人免费黄色播放视频| 亚洲精品aⅴ在线观看| 又大又黄又爽视频免费| 十分钟在线观看高清视频www| 嫩草影院入口| 晚上一个人看的免费电影| 精品一区二区三卡| 一级毛片黄色毛片免费观看视频| av福利片在线| 搡老乐熟女国产| 老司机亚洲免费影院| 亚洲精品乱码久久久v下载方式| 中国美白少妇内射xxxbb| 插逼视频在线观看| 最新的欧美精品一区二区| 草草在线视频免费看| 2018国产大陆天天弄谢| av电影中文网址| 狠狠精品人妻久久久久久综合| 国产毛片在线视频| 久久久久久久久久久久大奶| 最黄视频免费看| 人人澡人人妻人| 久久久久久人妻| 亚洲欧美精品自产自拍| 黄色怎么调成土黄色| 高清在线视频一区二区三区| 国产精品国产三级专区第一集| 亚洲,一卡二卡三卡| videos熟女内射| 国产永久视频网站| 久久午夜福利片| 久久婷婷青草| 99热国产这里只有精品6| 高清欧美精品videossex| 一区二区日韩欧美中文字幕 | 最新中文字幕久久久久| 精品人妻熟女av久视频| 欧美最新免费一区二区三区| 亚洲欧洲日产国产| 亚洲精品乱码久久久v下载方式| 大话2 男鬼变身卡| 中文字幕av电影在线播放| 午夜福利视频在线观看免费| 亚洲一级一片aⅴ在线观看| 在线 av 中文字幕| 一本一本久久a久久精品综合妖精 国产伦在线观看视频一区 | 久久这里有精品视频免费| 免费高清在线观看视频在线观看| 爱豆传媒免费全集在线观看| 国语对白做爰xxxⅹ性视频网站| 欧美日韩亚洲高清精品| 91久久精品电影网| 国产免费视频播放在线视频| 夜夜爽夜夜爽视频| 26uuu在线亚洲综合色| 人妻人人澡人人爽人人| 尾随美女入室| 在线观看三级黄色| 午夜精品国产一区二区电影| 午夜福利网站1000一区二区三区| 综合色丁香网| 亚洲国产毛片av蜜桃av| 日韩一本色道免费dvd| 亚洲欧美日韩卡通动漫| 另类亚洲欧美激情| 免费不卡的大黄色大毛片视频在线观看| 精品人妻熟女av久视频| 最近中文字幕2019免费版| 久久人人爽人人爽人人片va| 高清毛片免费看| 纵有疾风起免费观看全集完整版| 啦啦啦中文免费视频观看日本| 午夜影院在线不卡| 国产精品一国产av| 99久国产av精品国产电影| 国产伦理片在线播放av一区| 亚洲av福利一区| 久热久热在线精品观看| 国产永久视频网站| 亚洲综合精品二区| 亚洲,欧美,日韩| 一本—道久久a久久精品蜜桃钙片| 麻豆精品久久久久久蜜桃| .国产精品久久| 免费av中文字幕在线| 晚上一个人看的免费电影| 国产免费福利视频在线观看| 高清不卡的av网站| 日韩在线高清观看一区二区三区| 大码成人一级视频| 久久精品国产a三级三级三级| 亚洲精品乱码久久久久久按摩| 毛片一级片免费看久久久久| 91精品一卡2卡3卡4卡| 国产成人91sexporn| 99热6这里只有精品| 久久久久久久久久久免费av| 国产成人av激情在线播放 | 少妇被粗大猛烈的视频| 精品国产国语对白av| 亚洲国产精品国产精品| 麻豆成人av视频| 日本与韩国留学比较| 免费大片18禁| 欧美 日韩 精品 国产| 国产精品.久久久| 男女边摸边吃奶| 国产精品偷伦视频观看了| 多毛熟女@视频| av女优亚洲男人天堂| tube8黄色片| av.在线天堂| 亚洲天堂av无毛| 一级a做视频免费观看| 国产成人aa在线观看| 日韩成人伦理影院| 一区二区三区精品91| 亚洲情色 制服丝袜| 成人二区视频| 伦理电影大哥的女人| 国产成人免费观看mmmm| 99久久精品国产国产毛片| 一级毛片aaaaaa免费看小| 汤姆久久久久久久影院中文字幕| 校园人妻丝袜中文字幕| 亚洲欧美色中文字幕在线| 日本午夜av视频| 欧美xxxx性猛交bbbb| 大陆偷拍与自拍| 99九九线精品视频在线观看视频| 成人午夜精彩视频在线观看| 少妇人妻久久综合中文| 18禁动态无遮挡网站| 亚洲精品乱码久久久久久按摩| 午夜福利影视在线免费观看| .国产精品久久| 日韩成人av中文字幕在线观看| 在线观看免费视频网站a站| www.色视频.com| 妹子高潮喷水视频| 日韩av在线免费看完整版不卡| 一区二区三区乱码不卡18| 日韩,欧美,国产一区二区三区| 一级毛片电影观看| 久久狼人影院| 黑人高潮一二区| 纯流量卡能插随身wifi吗| 视频在线观看一区二区三区| 午夜激情av网站| 一级毛片黄色毛片免费观看视频| 好男人视频免费观看在线| 麻豆成人av视频| 国国产精品蜜臀av免费| h视频一区二区三区| 十分钟在线观看高清视频www| 欧美日韩亚洲高清精品| 亚洲天堂av无毛| 亚洲欧美日韩另类电影网站| 亚洲av欧美aⅴ国产| 国产在视频线精品| .国产精品久久| 最近中文字幕高清免费大全6| 日韩欧美一区视频在线观看| 中文精品一卡2卡3卡4更新| 国产乱人偷精品视频| 欧美人与性动交α欧美精品济南到 | 国产黄色免费在线视频| 51国产日韩欧美| 美女脱内裤让男人舔精品视频| 久久久国产一区二区| 妹子高潮喷水视频| 国产精品一区二区在线观看99| 亚洲精品国产色婷婷电影| 黄色欧美视频在线观看| 日韩中文字幕视频在线看片| videos熟女内射| 亚洲欧洲国产日韩| 亚洲美女搞黄在线观看| 免费播放大片免费观看视频在线观看| 国产欧美日韩一区二区三区在线 | av黄色大香蕉| 精品久久久久久电影网| 国产精品久久久久久久久免| 亚洲第一区二区三区不卡| 国产亚洲最大av| 免费黄网站久久成人精品| 国产精品一国产av| 999精品在线视频| 亚洲精品日韩在线中文字幕| 在线免费观看不下载黄p国产| 亚洲精品aⅴ在线观看| 免费观看的影片在线观看| .国产精品久久| 一级a做视频免费观看| 亚洲av综合色区一区| 亚洲精品亚洲一区二区| 精品一区二区三区视频在线| 人妻夜夜爽99麻豆av| 欧美日韩国产mv在线观看视频| 精品视频人人做人人爽| 成人国产麻豆网| 色吧在线观看| 国产亚洲av片在线观看秒播厂| 欧美bdsm另类| 内地一区二区视频在线| 亚洲怡红院男人天堂| 丰满饥渴人妻一区二区三| 国产有黄有色有爽视频| 亚洲av电影在线观看一区二区三区| 十八禁高潮呻吟视频| 日韩人妻高清精品专区| 国产成人a∨麻豆精品| 男女无遮挡免费网站观看| 欧美bdsm另类| 99久国产av精品国产电影| 色5月婷婷丁香| 各种免费的搞黄视频| 久久精品久久久久久久性| 全区人妻精品视频| 亚洲欧洲日产国产| 熟妇人妻不卡中文字幕| 大话2 男鬼变身卡| 狂野欧美激情性xxxx在线观看| 久热久热在线精品观看| 国产免费福利视频在线观看| 青青草视频在线视频观看| videos熟女内射| 免费人妻精品一区二区三区视频| 精品少妇内射三级| 日韩一区二区视频免费看| 26uuu在线亚洲综合色| 简卡轻食公司| 性高湖久久久久久久久免费观看| 午夜久久久在线观看| 国产爽快片一区二区三区| 久久久久久久久久久久大奶| 日日摸夜夜添夜夜爱| 久久这里有精品视频免费| 国产一区二区在线观看av| 亚洲精品成人av观看孕妇| 波野结衣二区三区在线| 国语对白做爰xxxⅹ性视频网站| 国产高清不卡午夜福利| 99久久精品国产国产毛片| av.在线天堂| 2021少妇久久久久久久久久久| 插逼视频在线观看| 女性被躁到高潮视频| 国产成人精品无人区| 在线 av 中文字幕| 亚洲精品亚洲一区二区| av不卡在线播放| 国产成人精品在线电影| 一级毛片电影观看| 国产爽快片一区二区三区| 成人毛片a级毛片在线播放| xxxhd国产人妻xxx| 国产一区有黄有色的免费视频| 欧美人与性动交α欧美精品济南到 | 亚洲欧美日韩另类电影网站| 熟女电影av网| 国产高清有码在线观看视频| 青春草视频在线免费观看| 亚洲欧美成人综合另类久久久| 在线免费观看不下载黄p国产| 美女脱内裤让男人舔精品视频| 日本爱情动作片www.在线观看| 秋霞伦理黄片| 少妇人妻久久综合中文| 国产亚洲一区二区精品| 成人毛片60女人毛片免费| videossex国产| 精品人妻熟女毛片av久久网站| 国产精品欧美亚洲77777| 精品亚洲成a人片在线观看| 69精品国产乱码久久久| 性色av一级| 午夜av观看不卡| 在线亚洲精品国产二区图片欧美 | 午夜影院在线不卡| 欧美另类一区| 91精品三级在线观看| 高清不卡的av网站| 亚洲久久久国产精品| 黑人猛操日本美女一级片| videos熟女内射| 免费人妻精品一区二区三区视频| 亚洲欧美清纯卡通| 久久国产精品大桥未久av| 丰满迷人的少妇在线观看| 新久久久久国产一级毛片| 母亲3免费完整高清在线观看 | 亚洲av在线观看美女高潮| 免费高清在线观看视频在线观看| 久久国内精品自在自线图片| 国产精品.久久久| 欧美性感艳星| 黄色欧美视频在线观看| 草草在线视频免费看| 热re99久久精品国产66热6| 天天操日日干夜夜撸| 王馨瑶露胸无遮挡在线观看| 久久久久久久久久成人| 男女高潮啪啪啪动态图| 精品久久久噜噜| 亚洲伊人久久精品综合| 美女视频免费永久观看网站| 这个男人来自地球电影免费观看 | 精品久久久噜噜| 免费不卡的大黄色大毛片视频在线观看| 美女视频免费永久观看网站| 日韩不卡一区二区三区视频在线| 国产一区有黄有色的免费视频| 国产精品免费大片| 色5月婷婷丁香| 91精品国产国语对白视频| 精品国产露脸久久av麻豆| 国产片特级美女逼逼视频| 视频在线观看一区二区三区| 久久久久久久大尺度免费视频| 日本vs欧美在线观看视频| 久久国产精品男人的天堂亚洲 | 亚洲五月色婷婷综合| 久久久久精品久久久久真实原创| 乱人伦中国视频| 在线观看三级黄色| 日韩成人伦理影院| 一区二区三区四区激情视频| 欧美日韩一区二区视频在线观看视频在线| 国产黄色视频一区二区在线观看| 日韩av不卡免费在线播放| av国产精品久久久久影院| 亚洲人成网站在线观看播放| 男女无遮挡免费网站观看| 日本色播在线视频| 99热全是精品| 在线看a的网站| 一区二区三区乱码不卡18| 国产免费现黄频在线看| 亚洲色图综合在线观看| 欧美+日韩+精品| 青春草亚洲视频在线观看| 99久久精品一区二区三区| 啦啦啦在线观看免费高清www| 免费黄频网站在线观看国产| 国产伦精品一区二区三区视频9| 午夜精品国产一区二区电影| 观看av在线不卡| 亚洲精品中文字幕在线视频| 日本与韩国留学比较| 人妻系列 视频| 久久久午夜欧美精品| 国产黄色视频一区二区在线观看| 天天操日日干夜夜撸| 精品一区二区三区视频在线| 永久免费av网站大全| 国产老妇伦熟女老妇高清| 亚洲国产精品一区二区三区在线| 春色校园在线视频观看| 欧美日韩一区二区视频在线观看视频在线| 成人无遮挡网站| 交换朋友夫妻互换小说| 日韩成人伦理影院| 热re99久久国产66热| 天天操日日干夜夜撸| 国产一级毛片在线| 久久久久视频综合| 中国美白少妇内射xxxbb| 青春草亚洲视频在线观看| 久久久国产精品麻豆| 亚洲国产色片| 日本色播在线视频| 欧美一级a爱片免费观看看| 黄片播放在线免费| 狠狠婷婷综合久久久久久88av| 久久精品国产亚洲网站| 一区二区av电影网| 亚洲精品久久成人aⅴ小说 | 春色校园在线视频观看| 欧美变态另类bdsm刘玥| av.在线天堂| 亚洲综合精品二区| 午夜福利在线观看免费完整高清在| 日本欧美国产在线视频| 三级国产精品欧美在线观看| 中文乱码字字幕精品一区二区三区| 国产成人精品久久久久久| 日本欧美国产在线视频| 久久精品国产亚洲av涩爱| 国产高清国产精品国产三级| 久久这里有精品视频免费| 一级毛片电影观看| 老女人水多毛片| xxx大片免费视频| 一级毛片aaaaaa免费看小| 九色成人免费人妻av| 大又大粗又爽又黄少妇毛片口| 亚洲av福利一区| 日韩欧美一区视频在线观看| 激情五月婷婷亚洲| 在线播放无遮挡| 国产精品女同一区二区软件| 国产探花极品一区二区| 中文字幕av电影在线播放| 成人免费观看视频高清| videossex国产| 精品熟女少妇av免费看| 久久久久网色| 22中文网久久字幕| 国产日韩欧美视频二区| 中文欧美无线码| 精品99又大又爽又粗少妇毛片| 少妇人妻 视频| videos熟女内射| 18禁裸乳无遮挡动漫免费视频| 午夜影院在线不卡| 精品久久国产蜜桃| 国产精品国产av在线观看| 18禁在线播放成人免费| 欧美激情 高清一区二区三区| 久久综合国产亚洲精品| 欧美日本中文国产一区发布| 国产视频首页在线观看| 麻豆成人av视频| 卡戴珊不雅视频在线播放| 美女脱内裤让男人舔精品视频| 国产精品嫩草影院av在线观看| 男的添女的下面高潮视频| 免费黄色在线免费观看| 国产精品无大码| 99久久人妻综合| 国产男人的电影天堂91| 欧美变态另类bdsm刘玥| 国产综合精华液| 少妇高潮的动态图| 性色avwww在线观看| 国产成人精品无人区| 97精品久久久久久久久久精品| av播播在线观看一区| 久久久久久久国产电影| 桃花免费在线播放| 青春草视频在线免费观看| 国产片内射在线| 伦精品一区二区三区| 一二三四中文在线观看免费高清| 人体艺术视频欧美日本| 美女国产高潮福利片在线看| 国产极品天堂在线| 特大巨黑吊av在线直播| 七月丁香在线播放| 久久婷婷青草| 黄片播放在线免费| 久久女婷五月综合色啪小说| 老司机亚洲免费影院| 日产精品乱码卡一卡2卡三| 亚洲精品国产av蜜桃| 18禁裸乳无遮挡动漫免费视频| av专区在线播放| 久久久久久久精品精品| 精品国产一区二区三区久久久樱花| 亚洲国产色片| 亚洲美女黄色视频免费看| 久久精品国产a三级三级三级| 中文精品一卡2卡3卡4更新| 亚洲性久久影院| 美女cb高潮喷水在线观看| 亚洲av国产av综合av卡| 久热久热在线精品观看| 爱豆传媒免费全集在线观看| 精品酒店卫生间| av女优亚洲男人天堂| 国产一区二区在线观看av| 欧美激情国产日韩精品一区| 午夜激情av网站| 成人国产av品久久久| 亚洲怡红院男人天堂| 人人妻人人爽人人添夜夜欢视频| 美女国产高潮福利片在线看| 国产一区二区在线观看av| 91精品三级在线观看| 亚洲人与动物交配视频| 97超视频在线观看视频| 性高湖久久久久久久久免费观看| 国产精品一二三区在线看|